344 related articles for article (PubMed ID: 30170319)
1. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
2. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
[TBL] [Abstract][Full Text] [Related]
3. A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.
Liu YA; Jin Q; Ding Q; Hao X; Mo T; Yan S; Zou Y; Huang Z; Zhang X; Gao W; Wu TY; Li C; Bursalaya B; Di Donato M; Zhang YQ; Deaton L; Shen W; Taylor B; Kamireddy A; Harb G; Li J; Jia Y; Schumacher AM; Laffitte B; Glynne R; Pan S; McNamara P; Molteni V; Loren J
ChemMedChem; 2020 Aug; 15(16):1562-1570. PubMed ID: 32613743
[TBL] [Abstract][Full Text] [Related]
4. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
[TBL] [Abstract][Full Text] [Related]
6. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
[TBL] [Abstract][Full Text] [Related]
7. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
9. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M
Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214
[TBL] [Abstract][Full Text] [Related]
10. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.
Kumar K; Suebsuwong C; Wang P; Garcia-Ocana A; Stewart AF; DeVita RJ
J Med Chem; 2021 Mar; 64(6):2901-2922. PubMed ID: 33682417
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
[TBL] [Abstract][Full Text] [Related]
12. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
13. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
[TBL] [Abstract][Full Text] [Related]
14. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
Yoon HR; Balupuri A; Choi KE; Kang NS
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
[TBL] [Abstract][Full Text] [Related]
15. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Lee Walmsley D; Murray JB; Dokurno P; Massey AJ; Benwell K; Fiumana A; Foloppe N; Ray S; Smith J; Surgenor AE; Edmonds T; Demarles D; Burbridge M; Cruzalegui F; Kotschy A; Hubbard RE
J Med Chem; 2021 Jul; 64(13):8971-8991. PubMed ID: 34143631
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
[TBL] [Abstract][Full Text] [Related]
17. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
[TBL] [Abstract][Full Text] [Related]
18. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
[TBL] [Abstract][Full Text] [Related]
19. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
[TBL] [Abstract][Full Text] [Related]
20. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]